Petros Grivas MD, PhDAssociate Professor, Department of Medicine, Division of Oncology; Clinical Director, Genitourinary Cancers Program, University of Washington; Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
Dr. Grivas has published widely in peer-reviewed journals and has authored more than 50 articles and book chapters. He is a member of the International Bladder Cancer Network, the Bladder Cancer Advocacy Network, the American Society of Clinical Oncology, and the American Association for Cancer Research, among other professional organizations.
With a strong interest in designing and conducting clinical trials, Dr. Grivas’s professional interests also involve clinical and translational research on experimental therapeutics in genitourinary cancers via a molecular biology–based approach aiming to translate results into clinical trials.
Having received his medical degree and a PhD in medical oncology from the University of Patras School of Medicine in Greece, Dr. Grivas came to the US for his internal medicine residency at Drexel University College of Medicine/Hahnemann University Hospital in Philadelphia. He completed a fellowship in hematology/oncology at the University of Michigan in 2013, and took part in the GME Scholars Health Care Administration and Leadership Program at Michigan between 2012 and 2014.
Dr. Grivas: (COI in the last 3 years): consulting for AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Driver, EMD Serono, Exelixis, Foundation Medicine, GlaxoSmithKline, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck, Mirati Therapeutics, Pfizer, Roche, Seattle Genetics, QED Therapeutics; participation in educational program for Bristol-Myers Squibb; and institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, Genentech, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Oncogenex, Pfizer, QED Therapeutics, GlaxoSmithKline.
His instituion receives research funding from Clovis Oncology, Bavarian Nordic, Immunomedics, Bristol-Myers Squibb, Debiopharm Group, and Pfizer.
Recent Contributions to PracticeUpdate:
- ASCO 2022: Abstract Recommendations From Dr. Petros Grivas for Kidney and Bladder Cancer
- Impact of Enfortumab Vedotin Discontinuation on Advanced Urothelial Carcinoma
- Efficacy of Sacituzumab Govitecan by Trop-2 Expression in Metastatic Urothelial Carcinoma
- Genomic Profiling of Small Cell Neuroendocrine Carcinomas of the Bladder
- Cancer and COVID-19: Outcomes and Risk Factors
- Sacituzumab Govitecan for Patients With Advanced Urothelial Carcinoma
- The Impact of Maintenance Avelumab on Time to Next Therapy Among Patients With Advanced Urothelial Carcinoma
- Neoadjuvant Nivolumab Plus Lirilumab for Muscle-Invasive Bladder Cancer
- New and Upcoming Data on Adjuvant Treatment of Urothelial Cancer
- New Data on Antibody-Drug Conjugates and Other Novel Compounds for Second-Line Urothelial Carcinoma Treatment